HSDD is defined as a decrease in or absence of thoughts and desires forany form of sexual activity. It can affect women of all ages, at any stage oflife and may put a strain on relationships. There is currently noFDA-approved treatment for this condition.
New research on the first compound in a class of drugs being newlyevaluated for HSDD in pre-menopausal women reveals the efficacy ofinvestigational compound flibanserin. This research - pivotal Phase III data- shows flibanserin increased the number of sexually satisfying events andsexual desire, and decreased associated distress in women suffering from HSDD.
The findings are being presented by Boehringer Ingelheim Pharmaceuticals,Inc. (BIPI) in several oral and poster presentations at the 12th Congress ofthe European Society for Sexual Medicine (ESSM) in Lyon, France and includedata specific to North America in the presentations.
NEWS: New First-in-Class Phase III Data on Drug for Female SexualDysfunction
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at:http://multivu.prnewswire.com/broadcast/40948/press.html
VIDEO PROVIDED BY: Boehringer Ingelheim Pharmaceuticals, Inc.
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313 EXT. 3SATELLITE FEEDS: Monday, November 16th, 2009 Monday, November 16th, 2009 1:00 PM - 1:15 PM ET 6:30 PM - 6:45 PM ET AMC 3 Galaxy 19 C-Band C-Band Transponder 3 Transponder 20 Downlink Freq. 3760 Horizontal Downlink Freq. 4100 Horizontal
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
